SCHEMBL29238247

SCHEMBL29238247

COCCN1CCC(COc2cc3ncnc(-c4ccc(NC(=O)C5(c6ccc(F)cc6)CC5)cc4)c3cc2OC)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 6/20 0.50
▸ KDR P35968 6/20 0.49
▸ AURKA O14965 3/20 0.48
▸ EGFR P00533 5/20 0.48
▸ PDGFRB P09619 5/20 0.45
▸ MET P08581 5/20 0.44
▸ FLT3 P36888 3/20 0.44
▸ AXL P30530 2/20 0.44
▸ PLK4 O00444 1/20 0.43
▸ STK25 O00506 1/20 0.43
▸ CIT O14578 1/20 0.43
▸ CHUK O15111 1/20 0.43
▸ MUSK O15146 1/20 0.43
▸ EPHB6 O15197 1/20 0.43
▸ MAPK13 O15264 1/20 0.43
▸ MAP3K13 O43283 1/20 0.43
▸ DAPK3 O43293 1/20 0.43
▸ MAP3K7 O43318 1/20 0.43
▸ RIPK2 O43353 1/20 0.43
▸ JAK2 O60674 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26535219 0.92 KIT (0.50) KITKDRAURKAEGFRPDGFRB
SCHEMBL26136263 0.87 KDR (0.48) KITKDRAURKAEGFRPDGFRB
SCHEMBL26099034 0.86 KIT (0.45) KITKDREGFRPDGFRBMET
SCHEMBL26100883 0.86 KIT (0.51) KITKDRAURKAEGFRPDGFRB
SCHEMBL30394281 0.86 EGFR (0.52) KITKDREGFRPDGFRBFLT3
SCHEMBL26099433 0.86 EGFR (0.52) KITKDREGFRPDGFRBFLT3
SCHEMBL26099032 0.84 EGFR (0.51) KITKDREGFRPDGFRBFLT3
SCHEMBL26103039 0.84 EGFR (0.50) KITKDREGFRPDGFRBFLT3
SCHEMBL30393851 0.82 AURKA (0.49) KITKDRAURKAEGFRPDGFRB
SCHEMBL26102438 0.82 AURKA (0.49) KITKDRAURKAEGFRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US claimed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP claimed
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 — — CN claimed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO claimed
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US disclosed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP disclosed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF PDGFRA, KIT, PDGFRB KIT 2/4885KDR 5/4885AURKA 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback